Dodd Robert L, Ryu Mi-Ryeong, Kamnerdsupaphon Pimkhuan, Gibbs Iris C, Chang Steven D, Adler John R
Department of Neurosurgery, Stanford University School of Medicine, Stanford, California 94305, USA.
Neurosurgery. 2006 Apr;58(4):674-85; discussion 674-85. doi: 10.1227/01.NEU.0000204128.84742.8F.
Microsurgical resection of benign intradural extramedullary spinal tumors is generally safe and successful, but patients with neurofibromatosis, recurrent tumors, multiple lesions, or medical problems that place them at higher surgical risk may benefit from alternatives to surgery. In this prospective study, we analyzed our preliminary experience with image-guided radiosurgical ablation of selected benign spinal neoplasms.
Since 1999, CyberKnife (Accuray, Inc., Sunnyvale, CA) radiosurgery was used to manage 51 patients (median age, 46 yr; range, 12-86 yr) with 55 benign spinal tumors (30 schwannomas, nine neurofibromas, 16 meningiomas) at Stanford University Medical Center. Total treatment doses ranged from 1600 to 3000 cGy delivered in consecutive daily sessions (1-5) to tumor volumes that varied from 0.136 to 24.6 cm.
Less than 1 year postradiosurgery, three of the 51 patients in this series (one meningioma, one schwannoma, and one neurofibroma) required surgical resection of their tumor because of persistent or worsening symptoms; only one of these lesions was larger radiographically. However, 28 of the 51 patients now have greater than 24 months clinical and radiographic follow-up. After a mean follow-up of 36 months, all of these later lesions were either stable (61%) or smaller (39%). Two patients died from unrelated causes. Radiation-induced myelopathy appeared 8 months postradiosurgery in one patient.
Although more patients studied over an even longer follow-up period are needed to determine the long-term efficacy of spinal radiosurgery for benign extra-axial neoplasms, short-term clinical benefits were observed in this prospective analysis. The present study demonstrates that CyberKnife radiosurgical ablation of such tumors is technically feasible and associated with low morbidity.
显微手术切除良性硬脊膜内髓外脊柱肿瘤通常是安全且成功的,但患有神经纤维瘤病、复发性肿瘤、多发性病变或存在使手术风险增加的内科问题的患者,可能会从手术替代方案中获益。在这项前瞻性研究中,我们分析了对选定的良性脊柱肿瘤进行影像引导下放射外科消融的初步经验。
自1999年以来,斯坦福大学医学中心使用射波刀(Accuray公司,加利福尼亚州桑尼维尔)放射外科治疗了51例患者(中位年龄46岁;范围12 - 86岁),这些患者患有55个良性脊柱肿瘤(30个神经鞘瘤、9个神经纤维瘤、16个脑膜瘤)。总治疗剂量范围为1600至3000 cGy,分连续每日疗程(1 - 5次)给予,肿瘤体积从0.136至24.6 cm不等。
放射外科治疗后不到1年,该系列51例患者中有3例(1例脑膜瘤、1例神经鞘瘤和1例神经纤维瘤)因症状持续或加重需要手术切除肿瘤;其中只有1个病变在影像学上增大。然而,51例患者中有28例目前有超过24个月的临床和影像学随访。平均随访36个月后,所有这些后期病变要么稳定(61%)要么缩小(39%)。2例患者死于无关原因。1例患者在放射外科治疗后8个月出现放射性脊髓病。
尽管需要对更多患者进行更长时间的随访以确定脊柱放射外科治疗良性轴外肿瘤的长期疗效,但在这项前瞻性分析中观察到了短期临床益处。本研究表明,射波刀放射外科消融此类肿瘤在技术上是可行的,且发病率较低。